Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Passiglia

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
Current Opinion in Pulmonary Medicine|April 30, 2021
The evolving paradigm of precision medicine in lung cancerFrancesco Passiglia, Giorgio V Scagliotti
Current Oncology Reports|January 2, 2021
Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?Fabrizio Tabbò, Francesco Passiglia, Silvia Novello
Current Treatment Options in Oncology|November 17, 2022
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has BegunMaristella Bungaro, Silvia Novello, Francesco Passiglia
Biomedicines|April 23, 2022
COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to RecoveryMaristella Bungaro, Francesco Passiglia, Giorgio V Scagliotti
Expert Opinion on Therapeutic Targets|July 8, 2014
Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?Christian Rolfo, Francesco Passiglia, Antonio Russo, et al.
Future Oncology (London, England)|July 11, 2018
Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practiceFrancesco Passiglia, Oriana Commendatore, Milena Vitali, et al.
Cancer Treatment Reviews|July 26, 2022
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLCFrancesco Passiglia, Umberto Malapelle, Nicola Normanno, et al.
Expert Opinion on Biological Therapy|August 4, 2015
Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?Giuseppe Bronte, Francesco Passiglia, Antonio Galvano, et al.
Cancer Treatment Reviews|March 20, 2021
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancerJordi Remon, Daniele Pignataro, Silvia Novello, et al.
Immunotargets and Therapy|February 12, 2021
Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?Francesco Passiglia, Maria Lucia Reale, Valeria Cetoretta, et al.
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
Current Opinion in Pulmonary Medicine|April 30, 2021
The evolving paradigm of precision medicine in lung cancerFrancesco Passiglia, Giorgio V Scagliotti
Current Oncology Reports|January 2, 2021
Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?Fabrizio Tabbò, Francesco Passiglia, Silvia Novello
Current Treatment Options in Oncology|November 17, 2022
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has BegunMaristella Bungaro, Silvia Novello, Francesco Passiglia
Biomedicines|April 23, 2022
COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to RecoveryMaristella Bungaro, Francesco Passiglia, Giorgio V Scagliotti
Expert Opinion on Therapeutic Targets|July 8, 2014
Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?Christian Rolfo, Francesco Passiglia, Antonio Russo, et al.
Future Oncology (London, England)|July 11, 2018
Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practiceFrancesco Passiglia, Oriana Commendatore, Milena Vitali, et al.
Cancer Treatment Reviews|July 26, 2022
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLCFrancesco Passiglia, Umberto Malapelle, Nicola Normanno, et al.
Expert Opinion on Biological Therapy|August 4, 2015
Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?Giuseppe Bronte, Francesco Passiglia, Antonio Galvano, et al.
Cancer Treatment Reviews|March 20, 2021
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancerJordi Remon, Daniele Pignataro, Silvia Novello, et al.
Immunotargets and Therapy|February 12, 2021
Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?Francesco Passiglia, Maria Lucia Reale, Valeria Cetoretta, et al.
Pageof 13